{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-027327","form_type":"8-K","ticker":"EXOZ","cik":"0002010788","company_name":"EXOZYMES INC.","filed_at":"2025-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.301308+00:00","generated_at":"2026-05-16T13:24:23.576897+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"eXoZymes achieves 100× scale-up of NCT production with >99% feedstock conversion","bullets":["Scaled NCT production 100-fold using proprietary exozyme cell-free platform, achieving >99% conversion from feedstock to product.","Batch executed under partner-operated conditions by Cayman Chemical, demonstrating process robustness and transferability.","CEO Michael Heltzen calls milestone an inflection point for cell-free enzyme-driven biomanufacturing.","Additional technical details and NCT extraction results expected in early 2026 after downstream analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-027327","json":"https://secwatch.observer/filing/0001493152-25-027327.json","markdown":"https://secwatch.observer/filing/0001493152-25-027327.md","text":"https://secwatch.observer/filing/0001493152-25-027327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2010788/000149315225027327/0001493152-25-027327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2010788/000149315225027327/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:24:23.576897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}